+ Follow ONGOING TELMISARTAN ALONE Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 431369
[Title] => Study shows CVD protection for Pinoys, other Asians
[Summary] => Majority of patients with cardiovascular disease (CVD) leading to heart attack and stroke do not receive appropriate treatment for various reasons.
[DatePublished] => 2009-01-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 424423
[Title] => Filipinos, other Asians benefit from telmisartan
[Summary] => The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) showed very promising results in Asian patients, as well as non-Asian patients, at high risk of cardiovascular disease (CVD).
[DatePublished] => 2008-12-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 234392
[Title] => GSK, Boehringer Ingelheim co-sponsor landmark trial
[Summary] => GlaxoSmithKline (GSK) joins forces with Boehringer Ingelheim (BI) to co-sponsor the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Program, the world’s largest ever cardiovascular protection trial using an angiotensin receptor blocker (ARB).
The program, which will enroll over 29,000 patients, will examine the preventive effects of telmisartan, either alone or in combination with the ACE inhibitor ramipril, on stroke, heart attack, cardiovascular death and hospitalization due to congestive heart failure.
[DatePublished] => 2004-01-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 231209
[Title] => Improving survival of high-risk heart patients
[Summary] => The greatest concern for high-risk heart patients is that their long-term survival may be significantly compromised.
Two of the world’s highly respected research-based pharmaceutical and healthcare companies have pooled their resources to sponsor what is believed to be the largest landmark cardiovascular protection trial of this decade which is expected to answer some questions on how to optimize cardiac care for patients at high risk and improve their long-term survival.
[DatePublished] => 2003-12-11 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 226916
[Title] => First patient enrolled in stroke prevention trial
[Summary] => The first patient has been enrolled in the Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) trial four weeks earlier than initially planned.
PRoFESS, the largest-ever secondary stroke prevention trial, will include a total of 15,500 patients in about 600 sites in more than 20 countries.
The principal investigator, Prof. Hans-Christoph Diener, randomized the first patient at the University of Essen in Germany.
[DatePublished] => 2003-11-06 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[5] => Array
(
[ArticleID] => 224399
[Title] => Trial seeks optimum hypertension mg’t
[Summary] => The growth in the medical understanding of heart disease that has been achieved with well-designed researches and clinical trials is one of the greatest achievements in medical history. Medical researchers all over the world have slowly but continuously provided the answers to many questions on heart-related diseases.
[DatePublished] => 2003-10-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[6] => Array
(
[ArticleID] => 221974
[Title] => ONTARGET: Protecting high-risk patients
[Summary] => Medical scientists and researchers are continuously undertaking researches and clinical trials which are answering a lot of previously unanswered questions in modern medicine.
Clinical trials have already convincingly shown that sustained management of hypertension significantly reduces the risk of cardiovascular events such as heart attack, heart failure, stroke and heart-related deaths.
Among the most effective medicines available to physicians is telmisartan, a medicine belonging to the angiotensin II receptor blocker class of drugs.
[DatePublished] => 2003-09-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 134000
[Title] => Study centers in 40 countries involved in heart pr
[Summary] => A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular protection trial.
Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced this at the European Society of Cardiology Congress in Stockholm, Sweden.
[DatePublished] => 2001-09-17 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
ONGOING TELMISARTAN ALONE
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 431369
[Title] => Study shows CVD protection for Pinoys, other Asians
[Summary] => Majority of patients with cardiovascular disease (CVD) leading to heart attack and stroke do not receive appropriate treatment for various reasons.
[DatePublished] => 2009-01-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 424423
[Title] => Filipinos, other Asians benefit from telmisartan
[Summary] => The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) showed very promising results in Asian patients, as well as non-Asian patients, at high risk of cardiovascular disease (CVD).
[DatePublished] => 2008-12-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 234392
[Title] => GSK, Boehringer Ingelheim co-sponsor landmark trial
[Summary] => GlaxoSmithKline (GSK) joins forces with Boehringer Ingelheim (BI) to co-sponsor the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Program, the world’s largest ever cardiovascular protection trial using an angiotensin receptor blocker (ARB).
The program, which will enroll over 29,000 patients, will examine the preventive effects of telmisartan, either alone or in combination with the ACE inhibitor ramipril, on stroke, heart attack, cardiovascular death and hospitalization due to congestive heart failure.
[DatePublished] => 2004-01-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 231209
[Title] => Improving survival of high-risk heart patients
[Summary] => The greatest concern for high-risk heart patients is that their long-term survival may be significantly compromised.
Two of the world’s highly respected research-based pharmaceutical and healthcare companies have pooled their resources to sponsor what is believed to be the largest landmark cardiovascular protection trial of this decade which is expected to answer some questions on how to optimize cardiac care for patients at high risk and improve their long-term survival.
[DatePublished] => 2003-12-11 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 226916
[Title] => First patient enrolled in stroke prevention trial
[Summary] => The first patient has been enrolled in the Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) trial four weeks earlier than initially planned.
PRoFESS, the largest-ever secondary stroke prevention trial, will include a total of 15,500 patients in about 600 sites in more than 20 countries.
The principal investigator, Prof. Hans-Christoph Diener, randomized the first patient at the University of Essen in Germany.
[DatePublished] => 2003-11-06 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[5] => Array
(
[ArticleID] => 224399
[Title] => Trial seeks optimum hypertension mg’t
[Summary] => The growth in the medical understanding of heart disease that has been achieved with well-designed researches and clinical trials is one of the greatest achievements in medical history. Medical researchers all over the world have slowly but continuously provided the answers to many questions on heart-related diseases.
[DatePublished] => 2003-10-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[6] => Array
(
[ArticleID] => 221974
[Title] => ONTARGET: Protecting high-risk patients
[Summary] => Medical scientists and researchers are continuously undertaking researches and clinical trials which are answering a lot of previously unanswered questions in modern medicine.
Clinical trials have already convincingly shown that sustained management of hypertension significantly reduces the risk of cardiovascular events such as heart attack, heart failure, stroke and heart-related deaths.
Among the most effective medicines available to physicians is telmisartan, a medicine belonging to the angiotensin II receptor blocker class of drugs.
[DatePublished] => 2003-09-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 134000
[Title] => Study centers in 40 countries involved in heart pr
[Summary] => A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular protection trial.
Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced this at the European Society of Cardiology Congress in Stockholm, Sweden.
[DatePublished] => 2001-09-17 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
January 15, 2009 - 12:00am
December 18, 2008 - 12:00am
January 8, 2004 - 12:00am
December 11, 2003 - 12:00am
November 6, 2003 - 12:00am
October 16, 2003 - 12:00am
September 25, 2003 - 12:00am
September 17, 2001 - 12:00am
